Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513701 | 0.82 | CNR2 (0.42) | P2RY14CA12CA1CA9CNR2 | |
| SCHEMBL7619637 | 0.81 | DRD2 (0.40) | P2RY14CNR2CYP17A1MAPK14PRKDC | |
| SCHEMBL1845748 | 0.79 | MAPK14 (0.39) | P2RY14CA12CA1CA9CNR2 | |
| SCHEMBL5001090 | 0.75 | TOP1 (0.40) | CA12CA1CA9CNR2CYP17A1 | |
| SCHEMBL5000911 | 0.75 | TOP1 (0.40) | CA12CA1CA9CNR2CYP17A1 | |
| SCHEMBL15385155 | 0.75 | TOP1 (0.40) | CA12CA1CA9CNR2CYP17A1 | |
| SCHEMBL8536509 | 0.73 | RAB9A (0.44) | P2RY14ACSS2 | |
| SCHEMBL2392134 | 0.72 | HDAC3 (0.39) | CA12CA1CA9CYP17A1MAPK14 | |
| SCHEMBL14262464 | 0.72 | CNR2 (0.40) | CA12CA1CA9CNR2CYP17A1 | |
| SCHEMBL6429116 | 0.70 | MAPK14 (0.38) | CA12CA1CA9CNR2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060287247-A1 | Binds nucleic acids; microbiocides for Grampositive infections and drug resistance bacteria | GENESOFT PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-7122626-B2 | Halogen-substitued thienyl compounds | GENESOFT PHARMCEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030130198-A1 | Halogen-substitued thienyl compounds | GENESOFT, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002088119-A1 | HALOGEN-SUBSTITUTED THIENYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | P2RY14 4173/4885CA12 4190/4885CA1 4663/4885 |
| US-20060287247-A1 | Binds nucleic acids; microbiocides for Grampositive infections and drug resistance bacteria | CNBP, TLR9, DDB1 | P2RY14 2485/4885CA12 4618/4885CA1 4821/4885 |
| US-20030130198-A1 | Halogen-substitued thienyl compounds | TOP1, TPR, PCNA | P2RY14 3881/4885CA12 4661/4885CA1 4835/4885 |
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | CASP3, BCL3, ME3 | P2RY14 2853/4885CA12 2623/4885CA1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.